FDA approves label expansion for Otonomy's Otiprio

Otonomy Inc. (NASDAQ:OTIC) said FDA approved an sNDA for Otiprio ciprofloxacin to treat acute otitis externa due to Pseudomonas aeruginosa or Staphylococcus aureus infection in patients ages six months and older...